Dactinomycin

For decades, the standard narrative around androgenetic alopecia has centered on androgens and the hair follicle cycle: dihydrotestosterone binds androgen receptors in dermal papilla cells, triggers premature catagen entry, and progressively miniaturizes terminal follicles into vellus-like structures. This model is correct as far as it goes. The problem is that it does not go far enough. A growing body of histological evidence shows that the tissue surrounding miniaturizing follicles undergoes significant structural remodeling — and that this remodeling may not be a passive consequence of miniaturization but an active contributor to its persistence. The perifollicular collagen axis, long treated as a footnote in AGA research, is returning to the center of the discussion. Understanding this axis matters for product development because it opens a distinct mechanistic lane — one that ingredients like DPO (diaminopyrimidine oxide, aminexil) are positioned to address. But understanding it also requires confronting the limitations of current evidence and the terminology errors that have accumulated around DPO's mechanism over three decades of commercialization. The histological case for perifollicular fibrosis in AGA rests on several foundational studies. Jaworsky, Kligman, and Murphy (1992, British Journal of Dermatology) characterized inflammatory infiltrates in male pattern alopecia, documenting perifollicular lymphocytic inflammation and collagenous streamers around miniaturizing follicles. Their work established that inflammation and fibrotic change are not incidental findings in AGA scalps but consistent features associated with progressive hair loss. Whiting (1993, Journal of the American Academy of Dermatology) introduced horizontal sectioning of scalp biopsies as a diagnostic methodology and described perifollicular collagenous thickening as a recurring observation in AGA specimens. While Whiting's work focused primarily on the diagnostic value of follicular miniaturization ratios, the fibrotic changes he documented have been cited repeatedly as evidence for matrix remodeling in AGA. More recent work has strengthened rather than weakened this thread. Umar, Tan, and Shitabata (2026, Clinical, Cosmetic and Investigational Dermatology) provide contemporary evidence for perifollicular fibrosis and inflammation as factors in AGA progression, supporting the view that collagen remodeling is not merely historical observation but an active area of investigation with therapeutic implications. Li et al. (2025, Skin Appendage Disorders) published a review framing perifollicular fibrosis explicitly as a modifiable axis in AGA, with collagen cross-linking pathways identified as potential intervention targets. This represents a meaningful shift from the older literature, which tended to describe fibrosis observationally rather than therapeutically. Liu et al. (2025, Nature Reviews Disease Primers) position AGA as a multifactorial condition involving androgen signaling, genetic susceptibility, Wnt pathway modulation, and inflammatory-fibrotic remodeling interactions. The inclusion of fibrotic remodeling as a named axis in a major primer-level review signals that the field has moved beyond treating it as peripheral. The central unresolved question is directionality: does perifollicular fibrosis contribute to miniaturization, or does miniaturization produce fibrosis as a secondary consequence? The honest answer is that the evidence supports both possibilities, and they are not mutually exclusive. The emerging consensus, as framed in contemporary reviews, favors a feedback model: microinflammation triggers TGF-β and Smad-driven myofibroblast activation, which drives collagen deposition and matrix stiffening, which in turn disrupts dermal papilla signaling and impairs follicular cycling. In this model, fibrosis is both consequence and contributor — a vicious cycle rather than a one-directional cause. For product development purposes, the practical implication is clear: whether fibrosis is primary or secondary, reducing perifollicular collagen rigidification is a rational strategy with histological support. The question is whether any available cosmetic ingredient can meaningfully do so. The foundational mechanistic study for DPO is Mahé, Buan, and Bernard (1996, Skin Pharmacology). Using RT-PCR in a structure-activity framework, they demonstrated that 2,4-diaminopyrimidine-3-oxide (aminexil) — the compound lacking the C6 piperidinyl group present in minoxidil — retains strong inhibition of lysyl hydroxylase mRNA expression in vitro. The significance of this finding is that it identified a mechanism for DPO that is independent of K_ATP channel biology. DPO was specifically selected from over 150 pyrimidine N-oxide derivatives because it retained anti-lysyl hydroxylase activity without the vasodilatory and antihypertensive effects associated with minoxidil's channel-opening activity. L'Oréal's original patent (US 4,973,474, filed 1989) covers 2,4-diaminopyrimidine-3-oxide derivatives for hair loss treatment and prevention on this basis. The broader context comes from Murad and Pinnell (1987, Journal of Biological Chemistry), who established that minoxidil suppresses lysyl hydroxylase activity in cultured fibroblasts at concentrations of 25–500 µM. Recovery was blocked by actinomycin D, confirming that the mechanism operates at the transcriptional level — this is mRNA suppression, not direct enzyme inhibition. No Ki or IC₅₀ values have been published for DPO against lysyl hydroxylase protein. Murad et al. (1992, Archives of Biochemistry and Biophysics) extended the SAR analysis, demonstrating that the C6 substituent structure affects which biological activities are retained. The pyrrolidine substitution in PDPO abolished lysyl hydroxylase inhibitory activity, while DPO — lacking any C6 substituent entirely — retained it. This SAR data is important because it shows that the lysyl hydroxylase mechanism is pharmacophore-dependent but separable from the potassium channel mechanism. This is where the terminology problem becomes critical. Lysyl hydroxylase (encoded by PLOD genes) is an Fe²⁺/2-oxoglutarate-dependent dioxygenase that hydroxylates lysine residues in procollagen, a modification required for subsequent stable cross-link formation. Lysyl oxidase (LOX) is a copper-dependent amine oxidase that catalyzes a different reaction — oxidative deamination of lysine and hydroxylysine residues in collagen and elastin to form allysine, enabling covalent cross-linking of mature fibers. These are fundamentally different enzymes. They have different substrates, different cofactors (iron versus copper), different genomic locations, and different positions in the collagen maturation cascade. Lysyl hydroxylase acts on procollagen intracellularly; lysyl oxidase acts on secreted collagen extracellularly. The published peer-reviewed evidence for DPO supports modulation of lysyl hydroxylase mRNA expression. The widespread description of DPO as a "lysyl oxidase inhibitor" in marketing materials, product pages, and even some corporate press materials does not reflect the primary literature. This conflation has persisted for over two decades, and it undermines the scientific credibility of DPO-based claims with the technical audience — dermatologists, formulation scientists, and regulatory reviewers — that matters most for serious product positioning. The SCCNFP (2000) concluded that DPO is "not a derivative of Minoxidil" and that its pharmacological activity is "unknown" — language that reflected the committee's assessment that the mechanism had not been fully characterized by pharmaceutical standards, even if L'Oréal's in-house research had identified the lysyl hydroxylase thread. Perifollicular fibrosis in AGA does not occur in isolation. It connects to the androgen-signaling axis through TGF-β1. Inui et al. (2003, Journal of Investigative Dermatology Symposium Proceedings) identified androgen-inducible TGF-β1 from dermal papilla cells as a key mediator suppressing epithelial growth in AGA. TGF-β1 is both a catagen-promoting signal and a potent pro-fibrotic factor — it drives Smad-dependent transcription of collagen genes, activates myofibroblasts, and promotes extracellular matrix deposition. Shin et al. (2013, BMB Reports) demonstrated that the induction of TGF-β1 by androgens in dermal papilla cells is mediated by reactive oxygen species. This ROS-TGF-β1 link is significant because it connects oxidative stress — a potentially modifiable factor — to the fibrotic cascade. NAC, an antioxidant and cysteine donor mechanistically similar to OTZ, was shown to suppress androgen-inducible TGF-β1 in dermal papilla cells in the same body of work. It is worth noting that TGF-β2, not TGF-β1, appears to be the primary isoform driving catagen induction in human hair follicles (Hibino and Nishiyama, 2004, Journal of Dermatological Science). TGF-β1 knockout mice show delayed catagen (Foitzik et al., 2000, FASEB Journal), confirming the isoform's involvement in follicle regression, but the relative contributions of β1 and β2 in human AGA remain an area of active investigation. The relevance of TGF-β biology to DPO is indirect but meaningful. TGF-β drives fibrosis through the same collagen deposition and maturation cascade that lysyl hydroxylase participates in. If DPO reduces lysyl hydroxylase expression — as the Mahé data supports — it addresses a downstream component of the TGF-β-driven fibrotic program. This creates a rational basis for combination strategies pairing anti-fibrotic (DPO) with antioxidant/GSH-supporting (OTZ) approaches, since they target different points in the same pathological cascade. However, this complementarity is conceptual. No published study has directly tested whether DPO and OTZ produce additive or synergistic effects on perifollicular collagen remodeling or any follicular endpoint. The clinical evidence for DPO is concentrated in product-level studies of multi-ingredient formulations: Reygagne et al. (2021, Dermatologic Therapy): An observational study of 527 subjects using Aminexil Clinical 5, a multi-ingredient product. Pull test reduction of 82% in men at day 90 (p < 0.01). Open-label, no placebo control, multiple L'Oréal-affiliated authors. Piraccini et al. (2011, Giornale Italiano di Dermatologia e Venereologia): Open-label study of aminexil plus arginine. Pull test reduction of 67.7% at 45 days, 82% at 90 days in men. No placebo, multi-ingredient. Jalilzadeh et al. (2024, BioImpacts): Controlled mouse model comparing 5% kopexil versus 5% minoxidil over 28 days. Kopexil showed significantly higher hair weight, follicle count, anagen percentage, and VEGF/HGF expression. Preclinical only. No published, independent, placebo-controlled, DPO-monotherapy human trial with phototrichogram or trichoscopy endpoints has been identified in the peer-reviewed literature. No study has demonstrated histological reversal of perifollicular fibrosis by DPO in human scalp biopsies. These are the evidence gaps that separate DPO's mechanistic rationale from pharmaceutical-grade clinical proof. A Vichy-sponsored RCT (NCT06590779) has been registered but results have not yet been published. Human scalp histology showing DPO-mediated reduction in perifollicular fibrosis has not been published. Lysyl oxidase enzyme kinetics (Ki/IC₅₀) for DPO have not been reported in peer-reviewed literature. Clinical outcomes are from multi-ingredient, sponsor-funded, open-label studies. DPO likely lacks K_ATP channel opening activity based on SAR data (Murad 1992), so combining it with DPO's "anti-fibrotic" positioning and K_ATP-related claims in the same product narrative is problematic unless two distinct active ingredients are being referenced. Competitive benchmarking against minoxidil — which has extensive, independent, controlled clinical evidence — should be framed carefully. For teams building scalp products around the fibrosis axis, this evidence landscape changes study design in three important ways. First, endpoint selection matters. Pull tests and subjective assessments are insufficient to substantiate an anti-fibrotic mechanism. Programs that take this pathway seriously need longer follow-up periods and structure-sensitive endpoints — trichoscopy-derived measures, possibly scalp biopsies with collagen staining in early-phase work. Second, attribution discipline matters. If the product is a multi-ingredient formula, the study should be designed to test the formula, not make claims about individual ingredients that the design cannot support. Alternatively, monotherapy arms can be included specifically to address attribution. Third, terminology accuracy matters. Describing DPO as a "lysyl oxidase inhibitor" when the published evidence supports lysyl hydroxylase transcriptional modulation is not merely imprecise — it is the kind of error that sophisticated buyers, dermatologists, and regulatory reviewers will notice and penalize. The collagen maturation modulation narrative is strong enough on its own merits; it does not need to borrow from a different enzyme. Most competing cosmetic hair actives — Redensyl, Capixyl, Procapil, caffeine, saw palmetto extracts — position around follicle stimulation, DHT reduction, or general antioxidant support. Very few address the perifollicular tissue environment directly. This creates a meaningful differentiation opportunity for products that can credibly claim anti-fibrotic or collagen-maturation-modulating activity. DPO's published evidence, while not pharmaceutical-grade, is specifically relevant to this lane. The Mahé 1996 data — lysyl hydroxylase mRNA suppression in a structure-activity framework — is mechanistically precise enough to survive scrutiny from technical buyers and regulatory reviewers, provided it is communicated accurately (lysyl hydroxylase, not lysyl oxidase; transcriptional modulation, not enzyme kinetics; in vitro, not clinical histological reversal). The broader opportunity is real. Perifollicular fibrosis represents a distinct pathological axis in AGA that is not well addressed by existing cosmetic actives. Products that can credibly position around this mechanism — with accurate science, transparent evidence hierarchy, and commitment to closing the data gaps — will have a structural advantage in a market increasingly demanding scientific rigor.

Each individual's risk of being diagnosed with primary bone sarcoma and their chances of recovery following diagnosis are influenced by a range of unique factors. In 2023, it is anticipated that 4K individuals of all ages in the United States will be diagnosed with primary bone sarcoma, including 2K males and 1.8K females. In 2020, approximately 400 cases were reported among those aged 15 to 19. LAS VEGAS, Nov. 28, 2023 /PRNewswire/ -- Bone sarcoma is a rare and aggressive form of cancer that originates in the bone tissue. It poses significant challenges during its treatment due to several factors. Firstly, its rarity often leads to delayed diagnosis, as symptoms can mimic other common conditions. Additionally, bone sarcoma typically affects children and young adults, making the emotional toll of the disease particularly challenging. Treatment often involves a combination of surgery, chemotherapy, and radiation therapy, which can be physically demanding and cause severe side effects. Moreover, because bone sarcoma tends to occur in the extremities, treatment may require complex and lengthy surgical procedures, potentially affecting mobility and quality of life. Furthermore, the risk of recurrence remains a constant concern, necessitating long-term monitoring and follow-up care. Despite these challenges, ongoing research and advancements in medical technology offer hope for improved outcomes and a better quality of life for those battling bone sarcoma. DelveInsight has recently released a series of epidemiology-based market reports focusing on benign bone sarcoma including Osteosarcoma Market Report, Ewing Sarcoma Market Report, and Chondrosarcoma Market Report. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032 segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these bone sarcoma markets individually. Osteosarcoma Market Osteosarcoma is a rare bone tumor affecting having an annual incidence of 3.4 cases per million. It is the most prevalent form of bone cancer, primarily developed in the osteoblast cells of bones, with a predilection for long bones near the knee joint. However, it can also manifest in other locations, including the upper leg, lower leg, upper arm, and virtually any bone in the body, including those in the pelvis, shoulder, and skull. It has the potential to invade adjacent tissues, such as tendons and muscles, and can metastasize to distant organs or other bones via the bloodstream. As per DelveInsight analysts, the total incident population of osteosarcoma in the 7MM was ~2K in 2022. The estimates show the highest incident cases of osteosarcoma in the United States with ~1K cases in 2022, and it is expected to increase by 2032. Osteosarcoma is commonly treated through a combination of chemotherapy, surgery, and radiation therapy. Despite some recent developments, limited progress has been achieved since the late 1980s when chemotherapy was added to surgical treatment, leading to improved survival rates. Radiation therapy impacts both normal and cancerous cells, causing various effects. Chemotherapeutic drugs like cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin calcium rescue (HDMTX) are widely used. Additionally, a few FDA-approved products, such as FUSILEV and KHAPZORY, are available for osteosarcoma treatment. As per DelveInsight analysis, the osteosarcoma market size is expected to increase at a significant CAGR by 2032. This growth would be fuelled by the increase in the patient pool and the expected entry of emerging therapies. Osteosarcoma Pipeline Therapies and Companies Lenvatinib: Eisai Naxitamab: Y-mAbs Therapeutics BAY80-6946: Bayer Vactosertib: MedPacto For a comprehensive view of the osteosarcoma market, check out the Osteosarcoma Market Assessment Ewing Sarcoma Market Ewing Sarcoma, a malignant tumor, typically initiates its growth within the bones, with a higher incidence among children and young adults, often manifesting during adolescence. Although it can originate in any bone, it predominantly affects the long bones, such as the thigh bone, shin bone, and upper arm bone. The pelvis bones are also frequently involved. In some cases, the tumor may originate in muscle and soft tissues. Common symptoms include bone stiffness, pain, swelling, or tenderness, along with tissue surrounding the affected bone. As per the assessment done by DelveInsight, the total incident cases of Ewing sarcoma in the 7MM comprised approximately 1.2K cases in 2022 and are projected to increase during the forecasted period. The management of Ewing sarcoma typically adopts a comprehensive approach, which may encompass surgery, chemotherapy, and radiation therapy. The National Comprehensive Cancer Network (NCCN) offers specific chemotherapy regimens for localized and metastatic Ewing sarcoma. For first-line treatment, NCCN suggests VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) for both initial presentations and as primary therapy for metastatic disease. In the second-line setting, NCCN recommends options like Cyclophosphamide and topotecan, Irinotecan + temozolomide ± Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin. As per the latest Ewing Sarcoma Market Report, the total Ewing sarcoma market size in the 7MM is approximately USD 26 million in 2022 and is projected to increase during the forecast period (2023–2032). The expected introduction of upcoming therapies and the deepened integration of early patient screening, medication management in secondary care, and diverse clinical setups, ongoing research into optimal implementation approaches, and a surge in public awareness will ultimately pave the way for the advancement of efficient treatment choices. Ewing Sarcoma Pipeline Therapies and Companies SECLIDEMSTAT (SP-2577): Salarius Pharmaceuticals ZEPZELCA (LURBINECTEDIN): Jazz Pharmaceuticals and PharmaMar VERZENIO (ABEMACICLIB): Eli Lilly IBRANCE (PALBOCICLIB): Pfizer MECBOTAMAB VEDOTIN (BA3011): Bioatla IOPOFOSINE I 131 (CLR 131): Cellectar Biosciences TP-1287: Sumitomo Pharma Oncology NBRX-109: Inhibrx Explore in-depth for a comprehensive understanding of the Ewing Sarcoma Clinical Trials Chondrosarcoma Market Chondrosarcoma comprises a group of bone tumors originating from cells that overproduce cartilage. Among these tumors, conventional chondrosarcoma is the most frequent type and is generally associated with slow growth. Conversely, rarer subtypes like dedifferentiated chondrosarcoma, myxoid chondrosarcoma, clear cell chondrosarcoma, and mesenchymal chondrosarcoma tend to exhibit a more aggressive growth pattern and have the potential to spread to distant body parts. DelveInsight estimated that the total incident cases of chondrosarcoma in the 7MM comprised approximately 2K cases in 2022 and are projected to increase during the forecasted period. The management approach for chondrosarcoma is contingent upon factors like tumor type, grade, and location, with the grading system serving as the most reliable indicator of clinical prognosis. It is firmly established that surgical intervention remains the gold standard and sole effective treatment for chondrosarcoma, as alternative modalities such as radiotherapy and chemotherapy exhibit limited responsiveness and resistance. Surgical options encompass curettage, radical resection, and amputation, each necessitating comprehensive clinical judgment and contingent upon variables such as lesion size, location, and malignant characteristics. Anticipated advancements in upcoming therapies and increased integration of early patient screening and medication within secondary care and other clinical settings, along with ongoing research to determine the best implementation methods, are expected to contribute to the development of more effective treatment options. However, chondrosarcoma, being an orphan disease, presents challenges in conducting clinical trials. Limited outcome data for locally advanced or metastatic patients underscore the need for new treatment approaches. Phase I trials, due to their small number of chondrosarcoma patients at varying dose levels, make it difficult to draw definitive conclusions. Nevertheless, some Phase II trials have yielded promising results, warranting further investigation. Encouraging retrospective studies could help augment the currently limited data. Urgent efforts to boost research studies on this orphan disease are imperative. As per DelveInsight analysis, the total market size of chondrosarcoma in the 7MM is approximately USD 9 million in 2022 and is projected to increase at a massive CAGR of 24.8% due to increasing awareness of the disease and the launch of the emerging therapy. Chondrosarcoma Pipeline Therapies and Companies INBRX-109: Inhibrx To access a complete analysis of the chondrosarcoma market, visit Chondrosarcoma Market Assessment Trending Oncology Reports Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including GAbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Oncolytic Virus Cancer Therapies Market Oncolytic Virus Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic virus cancer therapies companies, including Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others. Oncology Conference Coverage Services DelveInsight's Oncology Conference Coverage Services deliver a comprehensive examination of conference outcomes from a range of prominent events, such as ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, European CAR T-cell Meeting, and IASLC 2023. This in-depth analysis equips businesses with the insights they need for effective competitive intelligence and forecasting market trends, aiding in the development of future strategies. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP